Editorial
Antiphospholipid Antibodies and the Heart Lessons and Pitfalls for the Cardiologist Ronald A. Asherson, MD, FACP, FACR, FCP(SA), and Ricard Cervera, MD, PhD In a recent issue of Circulation, Nihoyannopoulos et all reported an increased prevalence of heart valve lesions in their patients with antiphospholipid antibodies (aPL). The aPL, including anticardiolipin antibodies and the lupus anticoagulant, are a group of antibodies directed predominantly against negatively charged phospholipids. 2 Their presence has been mainly demonstrated in sera of patients with systemic lupus erythematosus (SLE).3 However, they have been found occasionally in other connective tissue diseases4 as well as in drug-induced, malignant, and infectious disorders and in patients without any underlying immunological disorder.5. 6 A number of studies have found that patients with these antibodies are prone to repeated episodes of venous and/or arterial thrombosis, recurrent fetal loss, and thrombocytopenia. The association of aPL with these clinical events has been termed the antiphospholipid syndrome (APS).7 Recently, a wide spectrum of cardiac involvement has been reported in patients with aPL, raising the possibility that these cardiac manifestations may form part of the APS. It is our purpose in this editorial to briefly review the extent of these clinical manifestations.
Valve Lesions
Since the description by Libman and Sacks in 19248 of the valve lesions in four patients with a "hitherto undescribed form of valvular and mural endocarditis," there have been many reports of valve lesions in SLE. However, some of these lesions appear to be distinct from the classic Libman-Sacks type of verrucous endocarditis and demonstrate valve thickening or other types of dysfunction. It has been suggested that the improved survival of SLE patients may have altered the natural history of the cardiac involvement, allowing the emergence of chronic valvular dysfunction as the end stage of Libman-Sacks endocarditis.9 Interestingly, a number of recent echocardiographic studies have found that SLE patients possessing aPL have a signif-icantly higher prevalence of valvular lesions (both acute valve vegetations and chronic dysfunction) than those without."'10"11 In addition, the same types of heart valve lesions have been demonstrated in patients having APS without any underlying immunological disorder ("primary" APS).12 A further problem in these patients is the development of embolic cerebrovascular complications such as transient ischemic attacks (TIA), strokes, or multi-infarct dementia. 13 Whether aPL are the cause of these valvular lesions or epiphenomena accompanying more basic underlying immunological disturbances is unknown. Shapiro et al14 found selective deposition of immunoglobulins and complement along the vessel walls of vegetations, suggesting that circulating immune complexes may be involved in the growth and proliferation of these noninfective vegetations. The question of superadded thrombosis occurring on these damaged or abnormally thickened valves in the presence of aPL appears more likely than relating the thickened valve lesions to an antibody-mediated mechanism.
Pseudoinfective Endocarditis Our group15 drew attention to diagnostic difficulties that might arise in SLE patients presenting with the following combination of signs and serology: 1) fever, 2) cardiac murmurs with echocardiographic demonstration of valve vegetations, 3) splinter hemorrhages, 4) serological evidence of lupus activity, for example, high titers of antibodies to dsDNA and low serum complement levels, 5) high-to-moderate elevations of aPL, and 6) repeatedly culture-negative blood samples.
Infective endocarditis is a well known but rather uncommon complication of SLE. However, all of the above signs and serology are explicable on the basis of lupus activity and complications associated with the APS (i.e., valve vegetations and splinter hemorrhages). 16 Interestingly, similar features (hemodynamically significant verrucous endocarditis, high levels of aPL, and culture-negative blood samples) have also been recently reported in a patient with primary APS.17 It would take a brave clinician indeed to withhold antibiotic therapy from a patient with the above combinations of signs and serology. Anticoagulation (e.g., with heparin) is advised to minimize the risk of thromboembolism resulting from thrombotic valve lesions.
Three simple laboratory tests may also assist in making a differential diagnosis between true infective endocarditis and lupus activity with pseudoinfective endocarditis in a patient with the above combination of signs: 1) The white cell count: if low, would point to lupus activity alone; if high, to an infective etiology.
2) The C-reactive protein: lupus patients are usually unable to mount a response of this protein to lupus activity alone and elevation would imply infection.
3) The aPL level: if it is low positive only, this would be in keeping with infective endocarditis rather than clot deposition on a valve alone without infection. It has recently been shown that patients with simple infective endocarditis (e.g., on rheumatic valves or valves congenitally abnormal) may in fact demonstrate aPL, but the levels are never high positive. A moderate positive would also usually point toward lupus activity rather than infection.18
Intracardiac Thrombus
The endocardial surface may also be an important site for thrombus formation in patients with aPLs. Primary intracardial mural thrombi have been reported in these patients. 19, 20 It is important to stress that the presence of these thrombi may lead to diagnostic confusion; on occasion there may be difficulty in differentiation from a cardiac tumor, as in the case of atrial myxoma when using noninvasive imaging techniques.
Myocardial Infarction
In the general population, second only to involvement of the cerebral vasculature (TIAs, strokes, and dementia) is occlusion of major coronary vessels by thrombus. It is estimated that this complication may also be seen in approximately 5% of aPL-positive patients. This is particularly common in younger patients (under the age of 45 years) when other risk factors such as atherosclerosis are not as frequently encountered.
Myocardial infarctions (MI) are uncommon in SLE, occurring in 2-8% of patients.21 Early atherosclerosis related to long-term steroid administration has been incriminated, particularly in younger patients with this complication.22 Coronary arteritis is less frequent but has been demonstrated in several patients. 23 To these causes might now be added the presence of the aPL as a possible risk factor. Several patients with MI and aPL have recently been documented in separate studies.24, 25 We have reported a series of 13 patients with this complication26; six had classic lupus, three had "lupuslike" disease, and four appeared to have primary APS. Five had suffered from MI under the age of 30 years and four were in their early twenties. Other risk factors such as nephrotic syndrome, the use of oral contraceptives, long-term steroid therapy, excessive smoking, plasminogen activator deficiency, and deficiency of protein C were present in one patient each. Nine of the 13 had suffered from previous thromboembolism. Warfarin discontinuation or unsatisfactory coagulation control was a precipitating factor in several patients. It should be emphasized that the therapeutic International Normalization Ratio (INR) should be kept much higher in aPL patients than normally maintained as some are truly hypercoagulable, requiring as much as 20 mg of warfarin to maintain a therapeutic level. The INR should be kept at 3-3.5 rather than at 2-2.5.
In a series of 62 young survivors of MI (under the age of 45 years), recurrent cardiovascular events were found to be associated with aCL in eight of 13 patients with elevated aPL levels. These included cerebral infarctions (two), arterial occlusions of the lower limbs (two), new MI (three), pulmonary embolus (one), and deep vein thrombosis (one).27 This, however, has not been confirmed by other investigators.
On the other hand, in 83 patients who underwent coronary bypass graft surgery, aPL levels were found to be elevated in those patients with late bypass graft occlusions. 28 Therefore, in younger patients with MI, screening for the presence of these antibodies should be undertaken, particularly in those who have suffered other vascular occlusions. Long-term anticoagulation therapy may be necessary to prevent further occlusive events, both arterial and venous, and this may be combined with low-dose salicylates (80 mg/day).
Cardiomyopathy
Primary myocardial disease is difficult to diagnose in the presence of other more frequent conditions that might affect cardiac function secondarily such as renal failure, hypertension, endocarditis, and ischemic heart disease. Primary myocardial failure in lupus or lupus related conditions could be due to myocarditis, which is more common in patients with antibodies to ribonucleoproteins and may be associated with myositis. 29 Recently, however, patients with aPL and myocardial dysfunction, unexplained in the context of valve abnormalities or other obvious causes, have been documented. Leung et al,30 in a study of 75 consecutive lupus patients, found that aPL were significantly associated with left ventricular (global or isolated) dysfunction. Four of five patients with isolated left ventricular dysfunction had positive aPL.
An explanation for this type of abnormality in patients with aPL may be provided by the histopathological findings in two recent cases, both demonstrating striking thrombotic occlusions of the myocardial microcirculation in the absence of vasculitis. Brown et al31 described a 22-year-old woman with SLE who succumbed within 24 hours of admission with profound hypotension and peripheral circulatory collapse and who at necropsy demonstrated the presence of microthrombi in multiple organs including the heart. An essentially similar patient, a man with primary APS who had previously suffered MI, TIA, stroke, and aortic regurgitation and who had extensive livedo reticularis was described by Murphy and Leach.32 He died suddenly, and multiple platelet thrombi within the intramyocardial arteries were found at autopsy. Angiography in these patients may reveal normal coronary arteries because the disease involves the microcirculation.
Pulmonary Hypertension
The development of pulmonary hypertension (PHT) during the course of SLE or other autoimmune connective tissue disease is usually a harbinger of a fatal outcome within months or a few years despite therapy with vasodilators, prostacyclin analogues, anticoagulation, steroids, and/or immunosuppression. It usually resembles that seen in the primary idiopathic type of PHT with clear lung fields and no evidence of pulmonary thromboembolism. Thromboembolic PTH is distinctly unusual in these autoimmune diseases.
Interestingly, we have recently found a high prevalence (68%) of aPL in patients with PHT associated with SLE. Thirteen percent of a group of patients with primary idiopathic PHT were also found to demonstrate these antibodies at a low level, however. 33 The relation of aPL to PHT is not absolute, and their pathogenetic implications are unclear. However, they may be markers of a subset of patients prone to develop PHT.
In conclusion, it can be seen that the aPL-associated cardiac complications, most of which are explicable on the basis of thrombotic lesions either on valves or in the myocardial microcirculation, may mimic other similar conditions. The coagulopathy in these patients requires the careful and judicious use of appropriate anticoagulation therapy. For this reason, the estimation of aPL in cardiological practice assumes considerable importance today.
